1-adamantan-2-yl-3-naphthalen-2-yl-urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-adamantan-2-yl-3-naphthalen-2-yl-urea
• 英文别名: 1-(2-Adamantyl)-3-naphthalen-2-ylurea
• 化学式: C₂₁H₂₄N₂O
• 分子量: 320.434
• InChiKey: ZYCTXJXPQBBZDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
  申请人：Merck Sante

  公开号：EP1801098A1

  公开（公告）日：2007-06-27

  The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及公式I的2-金刚烷基脲衍生物，作为选择性抑制酶11-β-羟基类固醇脱氢酶1（11β-HSD1）的药物，并利用这些化合物治疗和预防代谢综合征、糖尿病、胰岛素抵抗、肥胖、脂质紊乱、青光眼、骨质疏松症、认知障碍、焦虑、抑郁、免疫紊乱、高血压以及其他疾病和症状。
• 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS
  申请人：Carniato Denis

  公开号：US20090227631A1

  公开（公告）日：2009-09-10

  The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及式I的2-金刚烷基脲衍生物，作为选择性抑制酶11-β-羟基类固醇脱氢酶1型（11β-HSD1）的抑制剂及其在代谢综合征、糖尿病、胰岛素抵抗、肥胖、脂质紊乱、青光眼、骨质疏松症、认知障碍、焦虑、抑郁、免疫障碍、高血压和其他疾病和病况的治疗和预防中的应用。
• 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS
  申请人：CARNIATO Denis

  公开号：US20120172396A1

  公开（公告）日：2012-07-05

  The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及式I的2-金刚烷基脲衍生物，作为选择性抑制酶11-β-羟基类固醇脱氢酶1型（11β-HSD1）的抑制剂，并且利用这些化合物治疗和预防代谢综合征、糖尿病、胰岛素抵抗、肥胖症、脂质紊乱、青光眼、骨质疏松症、认知障碍、焦虑症、抑郁症、免疫障碍、高血压和其他疾病和病况。
• Fused-ring compounds, pharmaceutical composition and uses thereof
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US10202388B2

  公开（公告）日：2019-02-12

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  本公开涉及一种式(I)的熔环化合物和/或其药学上可接受的盐、一种包含式(I)的熔环化合物和/或其药学上可接受的盐的药物组合物、其制备方法以及其在调节吲哚胺2，3-二氧化酶(IDO)和/或色氨酸2，3-二氧化酶(TDO)活性中的用途。本公开进一步提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫性疾病。
• FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US20180022752A1

  公开（公告）日：2018-01-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.